On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma

Inclusion Criteria: 1. Subjects voluntarily participate in clinical studies; 2. ECOG score 0-1 points; 3. Histologically confirmed large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and inert lymphoma transformed into diffuse large B-cell lymphoma; CD19 and/or CD20 positivity; 4. At least one measurable tumor lesion determined according to Lugano's criteria: the longest diameter of intranodal lesions\>1.5cm, and the longest diameter of extranodal lesions\>1.0cm. Exclusion Criteria: 1. Received other chimeric antigen receptor therapy or gene modified cell therapy before screening; 2. Subjects who were undergoing systemic steroid therapy during screening and were determined by the researchers to require long-term use of systemic steroid therapy during the treatment period (excluding inhalation or local use); 3. Any unstable heart disease, including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association \[NYHA\] classification ≥ III), and severe arrhythmia.